Latest Conference Articles

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

Montes' team found benefits in motor function, walking ability, and fatigue in patients to undergo nusinersen (Spinraza) for spinal muscular atrophy.

The Global Head of Neurodegeneration for Genentech talks about the progress of 2 promising monoclonal antibodies.

Treatment with volanesorsen shows efficacy in patients with FCS.

The vice president of Development Sciences for Biogen shared developments to come of the international MS PATHS collaboration.

Results from a questionnaire show that individuals living with FCS prove that communication among people in similar situations can improve a patient’s quality of life.

At the NLA Scientific Sessions in Las Vegas this morning, Akcea Therapeutics, presented a poster with data from the largest burden of illness study in patients with FCS to date.

Children receiving AVXS-101 have shown such improvement that researchers are calling for an update to the CHOP-INTEND scale used to track their progress.

Patients from 2 demographically-different studies switching from interferon therapy to Aubagio reported similar improvements.

The executive vice president and chief medical officer of Biogen explained how crucial it is for potential DMTs to attacki the alpha-synuclein protein.

The director of the Sports Neurology Program at Norton Healthcare and head of the NCAA Headache Task Force discussed trends in his popularizing field.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Results from Alder Biopharmaceutical’s phase 3 study demonstrated reductions in migraine following quarterly infusions of both 100 mg and 300 mg eptinezumab versus placebo in patients with episodic migraines.

Lead author Alexander D. Rae-Grant, MD, explains the measures taken to ensure the panel got their 16-year multiple sclerosis recommendations update right.

Researchers found that 100U of incobotulinumtoxinA significantly reduced unstimulated salivary flow rate during the 16-week trial and through the 48-week extension.

Already tasked with a burdensome regimen of therapy for nerve damage, some patients may just be looking for simpler relief.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

The investigative therapy for SMA reported various efficacy results in a phase 3 extension trial.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

A new study finding that 50% of low income Latino patients with MS suffer from depression is coupled with recent reports on their exclusion from clinical research.

How a litany of treatment options could be just a single breakthrough drug away.

How the brain processes thought and action can be heavily influenced by the size of the network it's exposed to.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

The investigatory therapy for secondary progressive MS returned even more promising post hoc analysis prior to its FDA consideration.

A wrist-worn neuromodulation device delivers a nerve stimulation pattern tailored to the patient’s tremor.

The investigational therapy is first being researched for safety and dosage rates before efficacy is considered.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

Sephy Philip, PharmD, discussed the results of the ANCHOR trial, as well as the subgroup analysis.